GraniteShares Advisors LLC Has $123,000 Holdings in Stryker Corporation $SYK

GraniteShares Advisors LLC lessened its position in shares of Stryker Corporation (NYSE:SYK) by 89.5% in the fourth quarter, according to its most recent disclosure with the Securities & Exchange Commission. The fund owned 351 shares of the medical technology company’s stock after selling 3,001 shares during the period. GraniteShares Advisors LLC’s holdings in Stryker were worth $123,000 at the end of the most recent reporting period.

Other hedge funds have also added to or reduced their stakes in the company. Brighton Jones LLC increased its stake in shares of Stryker by 15.4% in the 4th quarter. Brighton Jones LLC now owns 4,564 shares of the medical technology company’s stock valued at $1,643,000 after acquiring an additional 609 shares in the last quarter. Schnieders Capital Management LLC. bought a new position in Stryker in the 2nd quarter valued at about $205,000. Edgestream Partners L.P. boosted its position in shares of Stryker by 70.5% during the second quarter. Edgestream Partners L.P. now owns 1,523 shares of the medical technology company’s stock valued at $603,000 after buying an additional 630 shares during the last quarter. Guggenheim Capital LLC boosted its holdings in Stryker by 2.5% during the 2nd quarter. Guggenheim Capital LLC now owns 6,180 shares of the medical technology company’s stock worth $2,445,000 after acquiring an additional 152 shares during the last quarter. Finally, Marshall Wace LLP grew its position in Stryker by 107.9% in the 2nd quarter. Marshall Wace LLP now owns 5,700 shares of the medical technology company’s stock worth $2,255,000 after purchasing an additional 77,831 shares in the last quarter. 77.09% of the stock is currently owned by institutional investors.

Analyst Ratings Changes

A number of research analysts have issued reports on the company. BTIG Research upped their price objective on Stryker from $410.00 to $412.00 and gave the company a “buy” rating in a research note on Friday, January 30th. Robert W. Baird set a $437.00 target price on shares of Stryker in a report on Friday, January 30th. The Goldman Sachs Group set a $399.00 price target on shares of Stryker in a report on Friday, January 9th. Jefferies Financial Group reiterated a “buy” rating and issued a $465.00 price objective on shares of Stryker in a research report on Wednesday, March 4th. Finally, UBS Group dropped their target price on shares of Stryker from $400.00 to $380.00 and set a “neutral” rating for the company in a research report on Tuesday, March 17th. Fourteen analysts have rated the stock with a Buy rating and five have given a Hold rating to the stock. According to MarketBeat, the company currently has an average rating of “Moderate Buy” and an average target price of $427.50.

Insider Transactions at Stryker

In other Stryker news, Director Ronda E. Stryker sold 250,000 shares of the business’s stock in a transaction on Wednesday, February 4th. The shares were sold at an average price of $362.92, for a total transaction of $90,730,000.00. Following the transaction, the director directly owned 2,457,331 shares of the company’s stock, valued at approximately $891,814,566.52. The trade was a 9.23% decrease in their position. The sale was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through the SEC website. Insiders own 5.90% of the company’s stock.

Stryker Trading Down 0.0%

Shares of SYK stock opened at $331.48 on Friday. The company has a debt-to-equity ratio of 0.66, a current ratio of 1.89 and a quick ratio of 1.21. Stryker Corporation has a 1-year low of $319.32 and a 1-year high of $404.87. The stock has a market capitalization of $126.95 billion, a PE ratio of 39.46, a P/E/G ratio of 1.94 and a beta of 0.92. The business has a 50-day moving average of $357.10 and a 200 day moving average of $361.86.

Stryker (NYSE:SYK) last posted its quarterly earnings results on Thursday, January 29th. The medical technology company reported $4.47 EPS for the quarter, beating analysts’ consensus estimates of $4.40 by $0.07. Stryker had a net margin of 12.92% and a return on equity of 24.41%. The company had revenue of $7.17 billion during the quarter, compared to analyst estimates of $7.12 billion. During the same period in the prior year, the business posted $4.01 EPS. The firm’s revenue was up 11.4% compared to the same quarter last year. As a group, sell-side analysts anticipate that Stryker Corporation will post 13.47 earnings per share for the current year.

Stryker Announces Dividend

The firm also recently announced a quarterly dividend, which will be paid on Thursday, April 30th. Stockholders of record on Tuesday, March 31st will be paid a dividend of $0.88 per share. The ex-dividend date of this dividend is Tuesday, March 31st. This represents a $3.52 annualized dividend and a dividend yield of 1.1%. Stryker’s payout ratio is 41.90%.

About Stryker

Stryker Corporation is a global medical technology company that designs, manufactures and markets a broad range of products and services for use in hospitals, surgeons’ offices and other healthcare facilities. Its primary business activities span orthopedics (including joint replacement implants, trauma and extremities products), surgical equipment and operating room technologies (such as visualization, navigation and powered instruments), neurotechnology and spine solutions, and patient-handling and emergency medical equipment.